Venetoclax

Phase 3Active

0 views this week 0 watching⚡ Active🧬Featured in Oncology Pipeline Watch

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Lymphocytic Leukemia

Conditions

Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer

Trial Timeline

Sep 6, 2019 → Aug 1, 2027

NCT ID

NCT03844048

About Venetoclax

Venetoclax is a phase 3 stage product being developed by AbbVie for Chronic Lymphocytic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT03844048. Target conditions include Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Lymphocytic Leukemia were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03123029	Pre-clinical	Active	—	—	Chronic Lymphocytic Leukemia (CLL)
NCT07387471	Phase 2	Recruiting	Mar 23, 2026	Jul 1, 2028	Waldenstrom Macroglobulinemia
NCT06742086	Phase 1	Completed	Dec 19, 2024	Oct 8, 2025	Healthy Volunteer
NCT06070948	Phase 1	Withdrawn	Oct 5, 2023	Jul 28, 2025	Healthy Volunteers
NCT05768711	Phase 2	Active	Oct 4, 2023	Oct 1, 2028	Chronic Myeloid Leukemia
NCT05701215	Phase 2	Active	Aug 31, 2023	Jan 31, 2026	Chronic Myeloid Leukemia
NCT05909553	Phase 1	Completed	Jun 15, 2023	Sep 22, 2023	Healthy Volunteers
NCT04810598	Phase 1	Completed	Jul 8, 2021	Aug 16, 2022	Renal Impairment
NCT03844048	Phase 3	Active	Sep 6, 2019	Aug 1, 2027	Chronic Lymphocytic Leukemia
NCT03873857	Pre-clinical	Completed	Feb 25, 2019	Sep 12, 2022	Chronic Lymphocytic Leukemia (CLL)
NCT03567876	Phase 2	Completed	Sep 3, 2018	Oct 15, 2025	Lymphoma, Mantle-Cell
NCT03485547	Phase 1	Completed	Aug 23, 2018	Apr 16, 2025	Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT02966756	Phase 2	Recruiting	Oct 12, 2017	May 1, 2029	Chronic Lymphocytic Leukemia (CLL)
NCT02980731	Phase 3	Completed	Dec 13, 2016	Dec 29, 2021	Chronic Lymphocytic Leukemia (CLL)
NCT02756611	Phase 3	Completed	Jun 22, 2016	Mar 11, 2022	Chronic Lymphocytic Leukemia
NCT02141282	Phase 2	Completed	Sep 10, 2014	Dec 22, 2021	Chronic Lymphocytic Leukemia

Competing Products

20 competing products in Chronic Lymphocytic Leukemia

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	25
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	19
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	30